Review



dusp16  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Cell Signaling Technology Inc dusp16
    FBXL18 targeted <t>DUSP16</t> as a ubiquitination substrate. ( A-B ) The results of Co-IP and western blotting assays revealed the endogenous and exogenous interaction of FBXL18 and DUSP16. ( C-D ) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. ( E-F ) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. ( G-H ) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. ( I-J ) DUSP16 protein half-life in EC cells of LV-Control and LV-FBXL18 groups were evaluated by CHX chase assay. ( K-L ) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. ( M-N ) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. * P < 0.05; ** P < 0.01; *** P < 0.001
    Dusp16, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dusp16/DUSP16%2FMKP7+Rabbit+mAb/pmc12085810-91-9-11
    Average 90 stars, based on 8 article reviews
    dusp16 - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "FBXL18 promotes endometrial carcinoma progression via destabilizing DUSP16 and thus activating JNK signaling pathway"

    Article Title: FBXL18 promotes endometrial carcinoma progression via destabilizing DUSP16 and thus activating JNK signaling pathway

    Journal: Cancer Cell International

    doi: 10.1186/s12935-025-03808-9

    FBXL18 targeted DUSP16 as a ubiquitination substrate. ( A-B ) The results of Co-IP and western blotting assays revealed the endogenous and exogenous interaction of FBXL18 and DUSP16. ( C-D ) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. ( E-F ) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. ( G-H ) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. ( I-J ) DUSP16 protein half-life in EC cells of LV-Control and LV-FBXL18 groups were evaluated by CHX chase assay. ( K-L ) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. ( M-N ) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. * P < 0.05; ** P < 0.01; *** P < 0.001
    Figure Legend Snippet: FBXL18 targeted DUSP16 as a ubiquitination substrate. ( A-B ) The results of Co-IP and western blotting assays revealed the endogenous and exogenous interaction of FBXL18 and DUSP16. ( C-D ) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. ( E-F ) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. ( G-H ) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. ( I-J ) DUSP16 protein half-life in EC cells of LV-Control and LV-FBXL18 groups were evaluated by CHX chase assay. ( K-L ) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. ( M-N ) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. * P < 0.05; ** P < 0.01; *** P < 0.001

    Techniques Used: Ubiquitin Proteomics, Co-Immunoprecipitation Assay, Western Blot, Quantitative RT-PCR, Control, Comparison, Stable Transfection, Knockdown, Immunoprecipitation

    FBXL18 promoted EC cell malignancy via DUSP16-mediated activation of JNK signaling. ( A-C ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells of siNeg and siDUSP16 groups, and quantitative analysis. ( D-F ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells after overexpressing DUSP16, and quantitative analysis. ( G-I ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with LV-Ctrl + Vector, LV-Ctrl + DUSP16, LV-FBXL18 + Vector, LV-FBXL18 + DUSP16, and quantitative analysis. ( J-L ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with shNC + siNeg, shNC + siDUSP16, shFBXL18 + siNeg, shFBXL18 + siDUSP16, and quantitative analysis. * P < 0.05; ** P < 0.01; *** P < 0.001
    Figure Legend Snippet: FBXL18 promoted EC cell malignancy via DUSP16-mediated activation of JNK signaling. ( A-C ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells of siNeg and siDUSP16 groups, and quantitative analysis. ( D-F ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells after overexpressing DUSP16, and quantitative analysis. ( G-I ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with LV-Ctrl + Vector, LV-Ctrl + DUSP16, LV-FBXL18 + Vector, LV-FBXL18 + DUSP16, and quantitative analysis. ( J-L ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with shNC + siNeg, shNC + siDUSP16, shFBXL18 + siNeg, shFBXL18 + siDUSP16, and quantitative analysis. * P < 0.05; ** P < 0.01; *** P < 0.001

    Techniques Used: Activation Assay, Western Blot, Transfection, Plasmid Preparation

    Silence of FBXL18 inhibited EC growth in vivo. ( A ) Tumor volumes of shNC and shFBXL18 groups were determined at different defined time points. ( B ) Representative images of xenograft tumors in shNC and shFBXL18 groups. ( C ) Tumor weights of shNC and shFBXL18 groups were measured at the end point. ( E ) Western blot analysis of FBXL18, DUSP16, JNK, p-JNK, c-JUN, p-c-JUN, and EMT-related markers in tumor samples of shNC and shFBXL18 groups, and quantitative analysis. ( F ) qRT-PCR analysis of FBXL18 and DUSP16 in tumor samples of shNC and shFBXL18 groups. * P < 0.05; ** P < 0.01; *** P < 0.001
    Figure Legend Snippet: Silence of FBXL18 inhibited EC growth in vivo. ( A ) Tumor volumes of shNC and shFBXL18 groups were determined at different defined time points. ( B ) Representative images of xenograft tumors in shNC and shFBXL18 groups. ( C ) Tumor weights of shNC and shFBXL18 groups were measured at the end point. ( E ) Western blot analysis of FBXL18, DUSP16, JNK, p-JNK, c-JUN, p-c-JUN, and EMT-related markers in tumor samples of shNC and shFBXL18 groups, and quantitative analysis. ( F ) qRT-PCR analysis of FBXL18 and DUSP16 in tumor samples of shNC and shFBXL18 groups. * P < 0.05; ** P < 0.01; *** P < 0.001

    Techniques Used: In Vivo, Western Blot, Quantitative RT-PCR

    Related Articles

    other:

    Article Title: A FRET biosensor for necroptosis uncovers two different modes of the release of DAMPs
    Article Snippet: The following antibodies used in this study were obtained from the indicated sources: anti-phospho-RIPK1 (31122, Cell Signaling, 1:1000), anti-RIPK1 (610459, BD Biosciences, 1:1000), anti-phospho-RIPK3 (57220, Cell Signaling, 1:1000), anti-RIPK3 (IMG-5523-2, Immugenex, 1:3000), anti-phospho-MLKL (62233, Cell Signaling, 1:1000), anti-MLKL (3H1, made in house, 1:1000), anti-human MLKL (ab184718, Abcam, 1:1000), anti-cleaved caspase 3 (9661, Cell Signaling, 1:1000), anti-caspase-3 (9662, Cell Signaling, 1:1000), anti-actin (A2066, Sigma-Aldrich, 1:1000), anti-cytochrome c oxygenase subunit (COX) IV (Ab16056, Abcam, 1:1000), anti-tubulin (Sigma, T-5168, 1:40,000), anti-FLAG (M2, Sigma-Aldrich, 1:1000), anti-Myc (9E10, Sigma-Aldrich, 1:1000), anti-GFP (sc-8334, Santa Cruz, 1:5000), anti-GFP (66002-1-Ig, Proteintech, 1:5000), anti-mCherry (600-401-379, Rockland Immunochemicals, 1:10), anti-HMGB1 (ab18256, Abcam, 1:1000), anti-histone H3 (ab1791, Abcam, 1:1000), and HRP-conjugated donkey anti-rat IgG (712-035-153, Jackson ImmunoResearch, 1:10,000) antibodies.

    Western Blot:

    Article Title: DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death
    Article Snippet: Annexin V-FITC and 7-AAD (BioLegend) for apoptosis assay. .. !-actin (clone 13E5) Cell Signalling #4970, Bax Cell Signalling 2772, cmyc (Y69) Abcam#32072, Cleaved Caspase 3 (Asp175) Cell Signalling #9661, Cleaved Caspase 9 (Asp330) Cell Signalling #7237, Cytovhrome c Cell Signalling #4272, ERK (137F5) Cell Signalling #4695, JNK Cell Signalling #9252, MKP-7/DUSP16 (D5F4) Cell Signalling #5523, p38 Cell Signalling #9212, Phospho-ERK (Thr202/Tyr204) (197G2) Cell Signalling #4377, Phospho-JNK (Thr183/ Tyr185) (98F2) Cell Signalling #4671, Phospho-p38 (Thr180/Tyr182) (3D7) Cell Signalling #9215, VDAC (D73D12) Cell Signalling #4661, ATF2 (20F1) Cell signaling #9226, Anti-rabbit HRP-conjudgated secondary GE Healthcare #NA934 for western analysis. ..

    Saline:

    Article Title: Deficiency of smooth muscle cell ILF3 alleviates intimal hyperplasia via HMGB1 mRNA degradation-mediated regulation of the STAT3/DUSP16 axis.
    Article Snippet: Intimal hyperplasia is a complicated pathophysiological phenomenon attributable to in-stent restenosis, and the underlying mechanism remains unclear.. Interleukin enhancer-binding factor 3 (ILF3), a double-stranded RNAbinding protein involved in regulating mRNA stability, has been recently demonstrated to assume a crucial role in cardiovascular disease; nevertheless, its impact on intimal hyperplasia remains unknown.. In current study, we used samples of human restenotic arteries and rodent models of intimal hyperplasia, we found that vascular smooth muscle cell (VSMC) ILF3 expression was markedly elevated in human restenotic arteries and murine ligated carotid arteries.

    Incubation:

    Article Title: Deficiency of smooth muscle cell ILF3 alleviates intimal hyperplasia via HMGB1 mRNA degradation-mediated regulation of the STAT3/DUSP16 axis.
    Article Snippet: Intimal hyperplasia is a complicated pathophysiological phenomenon attributable to in-stent restenosis, and the underlying mechanism remains unclear.. Interleukin enhancer-binding factor 3 (ILF3), a double-stranded RNAbinding protein involved in regulating mRNA stability, has been recently demonstrated to assume a crucial role in cardiovascular disease; nevertheless, its impact on intimal hyperplasia remains unknown.. In current study, we used samples of human restenotic arteries and rodent models of intimal hyperplasia, we found that vascular smooth muscle cell (VSMC) ILF3 expression was markedly elevated in human restenotic arteries and murine ligated carotid arteries.

    Staining:

    Article Title: IL6 Modulates the Immune Status of the Tumor Microenvironment to Facilitate Metastatic Colonization of Colorectal Cancer Cells
    Article Snippet: .. After permeabilization using the Foxp3/Transcription Factor Staining Buffer set (#00-5523), the fixed cells were stained with pSTAT1 mAb (#9167, at 1:200 dilution, Cell Signaling Technology). ..



    Similar Products

    94
    ABclonal Biotechnology dusp16
    Dusp16, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dusp16/DUSP16+Rabbit+pAb/10__1158_slash_0008___5472__can___25___3743-119-40-41
    Average 94 stars, based on 1 article reviews
    dusp16 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Proteintech anti dusp16
    Anti Dusp16, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dusp16/DUSP16+Antibody/pmc12145754-92-34-35
    Average 93 stars, based on 1 article reviews
    anti dusp16 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    Thermo Fisher gene exp dusp16 hs01015508 m1
    Gene Exp Dusp16 Hs01015508 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dusp16/Gene+Exp%2E+DUSP16%2C+Hs01015508_m1/pmc12173946-388-84--1
    Average 94 stars, based on 1 article reviews
    gene exp dusp16 hs01015508 m1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc dusp16
    FBXL18 targeted <t>DUSP16</t> as a ubiquitination substrate. ( A-B ) The results of Co-IP and western blotting assays revealed the endogenous and exogenous interaction of FBXL18 and DUSP16. ( C-D ) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. ( E-F ) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. ( G-H ) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. ( I-J ) DUSP16 protein half-life in EC cells of LV-Control and LV-FBXL18 groups were evaluated by CHX chase assay. ( K-L ) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. ( M-N ) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. * P < 0.05; ** P < 0.01; *** P < 0.001
    Dusp16, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dusp16/DUSP16%2FMKP7+Rabbit+mAb/pmc12085810-91-9-11
    Average 90 stars, based on 1 article reviews
    dusp16 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    86
    Sangon Biotech dusp16
    Fig. 5 FBXL18 targeted <t>DUSP16</t> as a ubiquitination substrate. (A-B) The results of Co-IP and western blotting assays revealed the endogenous and exog enous interaction of FBXL18 and DUSP16. (C-D) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. (E-F) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. (G-H) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. (I-J) DUSP16 protein half-life in EC cells of LV-Control and LV- FBXL18 groups were evaluated by CHX chase assay. (K-L) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. (M-N) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. *P < 0.05; **P < 0.01; ***P < 0.001
    Dusp16, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dusp16/dusp16/pm40382593-60-3-12
    Average 86 stars, based on 1 article reviews
    dusp16 - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    90
    Sangon Biotech sirna specifically targeting dusp16
    FBXL18 targeted <t>DUSP16</t> as a ubiquitination substrate. ( A-B ) The results of Co-IP and western blotting assays revealed the endogenous and exogenous interaction of FBXL18 and DUSP16. ( C-D ) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. ( E-F ) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. ( G-H ) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. ( I-J ) DUSP16 protein half-life in EC cells of LV-Control and LV-FBXL18 groups were evaluated by CHX chase assay. ( K-L ) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. ( M-N ) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. * P < 0.05; ** P < 0.01; *** P < 0.001
    Sirna Specifically Targeting Dusp16, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dusp16/dusp16+sirna/pmc12085810-47-3-12
    Average 90 stars, based on 1 article reviews
    sirna specifically targeting dusp16 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    FBXL18 targeted DUSP16 as a ubiquitination substrate. ( A-B ) The results of Co-IP and western blotting assays revealed the endogenous and exogenous interaction of FBXL18 and DUSP16. ( C-D ) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. ( E-F ) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. ( G-H ) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. ( I-J ) DUSP16 protein half-life in EC cells of LV-Control and LV-FBXL18 groups were evaluated by CHX chase assay. ( K-L ) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. ( M-N ) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. * P < 0.05; ** P < 0.01; *** P < 0.001

    Journal: Cancer Cell International

    Article Title: FBXL18 promotes endometrial carcinoma progression via destabilizing DUSP16 and thus activating JNK signaling pathway

    doi: 10.1186/s12935-025-03808-9

    Figure Lengend Snippet: FBXL18 targeted DUSP16 as a ubiquitination substrate. ( A-B ) The results of Co-IP and western blotting assays revealed the endogenous and exogenous interaction of FBXL18 and DUSP16. ( C-D ) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. ( E-F ) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. ( G-H ) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. ( I-J ) DUSP16 protein half-life in EC cells of LV-Control and LV-FBXL18 groups were evaluated by CHX chase assay. ( K-L ) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. ( M-N ) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. * P < 0.05; ** P < 0.01; *** P < 0.001

    Article Snippet: The primary antibodies included FBXL18 (sc-100738, Santa Cruz, USA), DUSP16 (#5523, CST, USA), FLAG (#14793, CST, USA), HA (#3724, CST, USA).

    Techniques: Ubiquitin Proteomics, Co-Immunoprecipitation Assay, Western Blot, Quantitative RT-PCR, Control, Comparison, Stable Transfection, Knockdown, Immunoprecipitation

    FBXL18 promoted EC cell malignancy via DUSP16-mediated activation of JNK signaling. ( A-C ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells of siNeg and siDUSP16 groups, and quantitative analysis. ( D-F ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells after overexpressing DUSP16, and quantitative analysis. ( G-I ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with LV-Ctrl + Vector, LV-Ctrl + DUSP16, LV-FBXL18 + Vector, LV-FBXL18 + DUSP16, and quantitative analysis. ( J-L ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with shNC + siNeg, shNC + siDUSP16, shFBXL18 + siNeg, shFBXL18 + siDUSP16, and quantitative analysis. * P < 0.05; ** P < 0.01; *** P < 0.001

    Journal: Cancer Cell International

    Article Title: FBXL18 promotes endometrial carcinoma progression via destabilizing DUSP16 and thus activating JNK signaling pathway

    doi: 10.1186/s12935-025-03808-9

    Figure Lengend Snippet: FBXL18 promoted EC cell malignancy via DUSP16-mediated activation of JNK signaling. ( A-C ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells of siNeg and siDUSP16 groups, and quantitative analysis. ( D-F ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells after overexpressing DUSP16, and quantitative analysis. ( G-I ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with LV-Ctrl + Vector, LV-Ctrl + DUSP16, LV-FBXL18 + Vector, LV-FBXL18 + DUSP16, and quantitative analysis. ( J-L ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with shNC + siNeg, shNC + siDUSP16, shFBXL18 + siNeg, shFBXL18 + siDUSP16, and quantitative analysis. * P < 0.05; ** P < 0.01; *** P < 0.001

    Article Snippet: The primary antibodies included FBXL18 (sc-100738, Santa Cruz, USA), DUSP16 (#5523, CST, USA), FLAG (#14793, CST, USA), HA (#3724, CST, USA).

    Techniques: Activation Assay, Western Blot, Transfection, Plasmid Preparation

    Silence of FBXL18 inhibited EC growth in vivo. ( A ) Tumor volumes of shNC and shFBXL18 groups were determined at different defined time points. ( B ) Representative images of xenograft tumors in shNC and shFBXL18 groups. ( C ) Tumor weights of shNC and shFBXL18 groups were measured at the end point. ( E ) Western blot analysis of FBXL18, DUSP16, JNK, p-JNK, c-JUN, p-c-JUN, and EMT-related markers in tumor samples of shNC and shFBXL18 groups, and quantitative analysis. ( F ) qRT-PCR analysis of FBXL18 and DUSP16 in tumor samples of shNC and shFBXL18 groups. * P < 0.05; ** P < 0.01; *** P < 0.001

    Journal: Cancer Cell International

    Article Title: FBXL18 promotes endometrial carcinoma progression via destabilizing DUSP16 and thus activating JNK signaling pathway

    doi: 10.1186/s12935-025-03808-9

    Figure Lengend Snippet: Silence of FBXL18 inhibited EC growth in vivo. ( A ) Tumor volumes of shNC and shFBXL18 groups were determined at different defined time points. ( B ) Representative images of xenograft tumors in shNC and shFBXL18 groups. ( C ) Tumor weights of shNC and shFBXL18 groups were measured at the end point. ( E ) Western blot analysis of FBXL18, DUSP16, JNK, p-JNK, c-JUN, p-c-JUN, and EMT-related markers in tumor samples of shNC and shFBXL18 groups, and quantitative analysis. ( F ) qRT-PCR analysis of FBXL18 and DUSP16 in tumor samples of shNC and shFBXL18 groups. * P < 0.05; ** P < 0.01; *** P < 0.001

    Article Snippet: The primary antibodies included FBXL18 (sc-100738, Santa Cruz, USA), DUSP16 (#5523, CST, USA), FLAG (#14793, CST, USA), HA (#3724, CST, USA).

    Techniques: In Vivo, Western Blot, Quantitative RT-PCR

    Fig. 5 FBXL18 targeted DUSP16 as a ubiquitination substrate. (A-B) The results of Co-IP and western blotting assays revealed the endogenous and exog enous interaction of FBXL18 and DUSP16. (C-D) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. (E-F) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. (G-H) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. (I-J) DUSP16 protein half-life in EC cells of LV-Control and LV- FBXL18 groups were evaluated by CHX chase assay. (K-L) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. (M-N) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. *P < 0.05; **P < 0.01; ***P < 0.001

    Journal: Cancer cell international

    Article Title: FBXL18 promotes endometrial carcinoma progression via destabilizing DUSP16 and thus activating JNK signaling pathway.

    doi: 10.1186/s12935-025-03808-9

    Figure Lengend Snippet: Fig. 5 FBXL18 targeted DUSP16 as a ubiquitination substrate. (A-B) The results of Co-IP and western blotting assays revealed the endogenous and exog enous interaction of FBXL18 and DUSP16. (C-D) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. (E-F) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. (G-H) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. (I-J) DUSP16 protein half-life in EC cells of LV-Control and LV- FBXL18 groups were evaluated by CHX chase assay. (K-L) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. (M-N) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. *P < 0.05; **P < 0.01; ***P < 0.001

    Article Snippet: SiRNA specifically targeting DUSP16 or negative control siRNA (siNeg) were obtained from Sangon Biotech (Shanghai, China).

    Techniques: Ubiquitin Proteomics, Co-Immunoprecipitation Assay, Western Blot, Quantitative RT-PCR, Control, Comparison, Stable Transfection, Knockdown, Immunoprecipitation

    Fig. 7 Silence of FBXL18 inhibited EC growth in vivo. (A) Tumor volumes of shNC and shFBXL18 groups were determined at different defined time points. (B) Representative images of xenograft tumors in shNC and shFBXL18 groups. (C) Tumor weights of shNC and shFBXL18 groups were measured at the end point. (E) Western blot analysis of FBXL18, DUSP16, JNK, p-JNK, c-JUN, p-c-JUN, and EMT-related markers in tumor samples of shNC and shFBXL18 groups, and quantitative analysis. (F) qRT-PCR analysis of FBXL18 and DUSP16 in tumor samples of shNC and shFBXL18 groups. *P < 0.05; **P < 0.01; ***P < 0.001

    Journal: Cancer cell international

    Article Title: FBXL18 promotes endometrial carcinoma progression via destabilizing DUSP16 and thus activating JNK signaling pathway.

    doi: 10.1186/s12935-025-03808-9

    Figure Lengend Snippet: Fig. 7 Silence of FBXL18 inhibited EC growth in vivo. (A) Tumor volumes of shNC and shFBXL18 groups were determined at different defined time points. (B) Representative images of xenograft tumors in shNC and shFBXL18 groups. (C) Tumor weights of shNC and shFBXL18 groups were measured at the end point. (E) Western blot analysis of FBXL18, DUSP16, JNK, p-JNK, c-JUN, p-c-JUN, and EMT-related markers in tumor samples of shNC and shFBXL18 groups, and quantitative analysis. (F) qRT-PCR analysis of FBXL18 and DUSP16 in tumor samples of shNC and shFBXL18 groups. *P < 0.05; **P < 0.01; ***P < 0.001

    Article Snippet: SiRNA specifically targeting DUSP16 or negative control siRNA (siNeg) were obtained from Sangon Biotech (Shanghai, China).

    Techniques: In Vivo, Western Blot, Quantitative RT-PCR

    FBXL18 targeted DUSP16 as a ubiquitination substrate. ( A-B ) The results of Co-IP and western blotting assays revealed the endogenous and exogenous interaction of FBXL18 and DUSP16. ( C-D ) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. ( E-F ) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. ( G-H ) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. ( I-J ) DUSP16 protein half-life in EC cells of LV-Control and LV-FBXL18 groups were evaluated by CHX chase assay. ( K-L ) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. ( M-N ) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. * P < 0.05; ** P < 0.01; *** P < 0.001

    Journal: Cancer Cell International

    Article Title: FBXL18 promotes endometrial carcinoma progression via destabilizing DUSP16 and thus activating JNK signaling pathway

    doi: 10.1186/s12935-025-03808-9

    Figure Lengend Snippet: FBXL18 targeted DUSP16 as a ubiquitination substrate. ( A-B ) The results of Co-IP and western blotting assays revealed the endogenous and exogenous interaction of FBXL18 and DUSP16. ( C-D ) qRT-PCR analysis of DUSP16 mRNA levels after silencing or overexpressing FBXL18 in KLE and Ishikawa cells. ( E-F ) Western blot analysis of DUSP16 protein level in EC cells of shNC and shFBXL18 groups, and quantitative analysis. ( G-H ) Western blot analysis of DUSP16 protein level in EC cells after overexpressing FBXL18, and quantitative analysis. ( I-J ) DUSP16 protein half-life in EC cells of LV-Control and LV-FBXL18 groups were evaluated by CHX chase assay. ( K-L ) Comparison of DUSP16 protein half-life in EC cells stably knockdown of FBXL18 and control cells. ( M-N ) The ubiquitination status of endogenous DUSP16 after silencing or overexpressing FBXL18 in EC cells were determined by immunoprecipitation and western blotting. * P < 0.05; ** P < 0.01; *** P < 0.001

    Article Snippet: SiRNA specifically targeting DUSP16 or negative control siRNA (siNeg) were obtained from Sangon Biotech (Shanghai, China).

    Techniques: Ubiquitin Proteomics, Co-Immunoprecipitation Assay, Western Blot, Quantitative RT-PCR, Control, Comparison, Stable Transfection, Knockdown, Immunoprecipitation

    FBXL18 promoted EC cell malignancy via DUSP16-mediated activation of JNK signaling. ( A-C ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells of siNeg and siDUSP16 groups, and quantitative analysis. ( D-F ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells after overexpressing DUSP16, and quantitative analysis. ( G-I ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with LV-Ctrl + Vector, LV-Ctrl + DUSP16, LV-FBXL18 + Vector, LV-FBXL18 + DUSP16, and quantitative analysis. ( J-L ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with shNC + siNeg, shNC + siDUSP16, shFBXL18 + siNeg, shFBXL18 + siDUSP16, and quantitative analysis. * P < 0.05; ** P < 0.01; *** P < 0.001

    Journal: Cancer Cell International

    Article Title: FBXL18 promotes endometrial carcinoma progression via destabilizing DUSP16 and thus activating JNK signaling pathway

    doi: 10.1186/s12935-025-03808-9

    Figure Lengend Snippet: FBXL18 promoted EC cell malignancy via DUSP16-mediated activation of JNK signaling. ( A-C ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells of siNeg and siDUSP16 groups, and quantitative analysis. ( D-F ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells after overexpressing DUSP16, and quantitative analysis. ( G-I ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with LV-Ctrl + Vector, LV-Ctrl + DUSP16, LV-FBXL18 + Vector, LV-FBXL18 + DUSP16, and quantitative analysis. ( J-L ) Western blot analysis of DUSP16, JNK, p-JNK, c-JUN, and p-c-JUN levels in EC cells transfected with shNC + siNeg, shNC + siDUSP16, shFBXL18 + siNeg, shFBXL18 + siDUSP16, and quantitative analysis. * P < 0.05; ** P < 0.01; *** P < 0.001

    Article Snippet: SiRNA specifically targeting DUSP16 or negative control siRNA (siNeg) were obtained from Sangon Biotech (Shanghai, China).

    Techniques: Activation Assay, Western Blot, Transfection, Plasmid Preparation

    Silence of FBXL18 inhibited EC growth in vivo. ( A ) Tumor volumes of shNC and shFBXL18 groups were determined at different defined time points. ( B ) Representative images of xenograft tumors in shNC and shFBXL18 groups. ( C ) Tumor weights of shNC and shFBXL18 groups were measured at the end point. ( E ) Western blot analysis of FBXL18, DUSP16, JNK, p-JNK, c-JUN, p-c-JUN, and EMT-related markers in tumor samples of shNC and shFBXL18 groups, and quantitative analysis. ( F ) qRT-PCR analysis of FBXL18 and DUSP16 in tumor samples of shNC and shFBXL18 groups. * P < 0.05; ** P < 0.01; *** P < 0.001

    Journal: Cancer Cell International

    Article Title: FBXL18 promotes endometrial carcinoma progression via destabilizing DUSP16 and thus activating JNK signaling pathway

    doi: 10.1186/s12935-025-03808-9

    Figure Lengend Snippet: Silence of FBXL18 inhibited EC growth in vivo. ( A ) Tumor volumes of shNC and shFBXL18 groups were determined at different defined time points. ( B ) Representative images of xenograft tumors in shNC and shFBXL18 groups. ( C ) Tumor weights of shNC and shFBXL18 groups were measured at the end point. ( E ) Western blot analysis of FBXL18, DUSP16, JNK, p-JNK, c-JUN, p-c-JUN, and EMT-related markers in tumor samples of shNC and shFBXL18 groups, and quantitative analysis. ( F ) qRT-PCR analysis of FBXL18 and DUSP16 in tumor samples of shNC and shFBXL18 groups. * P < 0.05; ** P < 0.01; *** P < 0.001

    Article Snippet: SiRNA specifically targeting DUSP16 or negative control siRNA (siNeg) were obtained from Sangon Biotech (Shanghai, China).

    Techniques: In Vivo, Western Blot, Quantitative RT-PCR